NO951775L - Nye 3,3-difenylpropylaminer, deres anvendelse og fremstilling - Google Patents

Nye 3,3-difenylpropylaminer, deres anvendelse og fremstilling

Info

Publication number
NO951775L
NO951775L NO951775A NO951775A NO951775L NO 951775 L NO951775 L NO 951775L NO 951775 A NO951775 A NO 951775A NO 951775 A NO951775 A NO 951775A NO 951775 L NO951775 L NO 951775L
Authority
NO
Norway
Prior art keywords
compounds
diphenylpropylamines
methyl
preparation
formula
Prior art date
Application number
NO951775A
Other languages
English (en)
Other versions
NO951775D0 (no
NO305477B1 (no
Inventor
Rolf Arne Johansson
Pinchas Moses
Lisbeth Nilverbant
Bengt Aake Sparf
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20387730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO951775(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO951775L publication Critical patent/NO951775L/no
Publication of NO951775D0 publication Critical patent/NO951775D0/no
Publication of NO305477B1 publication Critical patent/NO305477B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
NO951775A 1992-11-06 1995-05-05 Nye 3,3-difenylpropylaminer, farmas°ytiske preparater inneholdende slike forbindelser, og deres anvendelse NO305477B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203318A SE9203318D0 (sv) 1992-11-06 1992-11-06 Novel 3,3-diphenylpropylamines, their use and preparation
PCT/SE1993/000927 WO1994011337A1 (en) 1992-11-06 1993-11-05 Novel 3,3-diphenylpropylamines, their use and preparation

Publications (3)

Publication Number Publication Date
NO951775L true NO951775L (no) 1995-05-05
NO951775D0 NO951775D0 (no) 1995-05-05
NO305477B1 NO305477B1 (no) 1999-06-07

Family

ID=20387730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951775A NO305477B1 (no) 1992-11-06 1995-05-05 Nye 3,3-difenylpropylaminer, farmas°ytiske preparater inneholdende slike forbindelser, og deres anvendelse

Country Status (14)

Country Link
US (4) USRE39667E1 (no)
EP (1) EP0667852B1 (no)
JP (1) JP3343256B2 (no)
AT (1) ATE164828T1 (no)
AU (1) AU672458B2 (no)
CA (1) CA2148827C (no)
DE (1) DE69317898T2 (no)
DK (1) DK0667852T3 (no)
ES (1) ES2117155T3 (no)
FI (1) FI120256B (no)
HU (1) HU224916B1 (no)
NO (1) NO305477B1 (no)
SE (1) SE9203318D0 (no)
WO (1) WO1994011337A1 (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
EP0938314A1 (en) * 1996-07-01 1999-09-01 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r)-trihexyphenidyl
WO1998024431A1 (en) * 1996-12-02 1998-06-11 Kyorin Pharmaceutical Co., Ltd. Novel n-substituted pyrrolidine derivatives and process for preparing the same
SE9701144D0 (sv) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
CZ302630B6 (cs) 1998-08-27 2011-08-10 Pharmacia & Upjohn Ab Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
DE60021749T2 (de) 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
AU2001242744B2 (en) 2000-03-24 2005-07-21 Meiji Seika Kaisha Ltd Diphenylalkylamine derivatives useful as opioid delta receptor ligands
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
CA2442281C (en) * 2001-03-27 2010-06-08 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
ATE418534T1 (de) * 2001-10-26 2009-01-15 Pharmacia & Upjohn Co Llc Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
BR0206300A (pt) * 2001-11-05 2008-04-08 Upjohn Co composição farmacêutica para tratar distúrbio urinário em um mamìfero e uso
WO2003039524A1 (en) * 2001-11-09 2003-05-15 Pharmacia Ab Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
AU2002360717A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Controlled release dosage form having improved drug release properties
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7005449B2 (en) * 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
NZ537584A (en) * 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) * 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
EP1620389A1 (en) 2003-04-25 2006-02-01 Pharmacia & Upjohn Company LLC Halogen substituted 3,3-diphenylpropylamines (tolterodine) having antimuscarinic activity
WO2004105692A2 (en) * 2003-05-23 2004-12-09 Bridge Pharma, Inc. Smooth muscle spasmolytic agents
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
JP5250205B2 (ja) * 2003-12-24 2013-07-31 シプラ・リミテッド トルテロジン、その組成物及び使用、及びその製造方法
WO2005082340A2 (en) 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
JP2007527922A (ja) * 2005-01-10 2007-10-04 テバ ファーマシューティカル インダストリーズ リミティド 実質的に純粋なトルテロジンタルトレート及びその調製方法
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists
WO2006124413A2 (en) 2005-05-13 2006-11-23 Novartis Ag Methods for treating drug resistant cancer
JP2007169278A (ja) * 2005-12-20 2007-07-05 Pfizer Prod Inc Luts処置用の医薬組合せ
MX2008011963A (es) 2006-03-20 2008-10-01 Pfizer Ltd Derivados de amina.
KR101453318B1 (ko) * 2006-05-31 2014-10-21 유씨비 매뉴팩처링 아일랜드 리미티드 치환 히드록시메틸 페놀의 새로운 합성
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
IES20060424A2 (en) 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
CA2648333C (en) 2006-06-09 2014-04-29 Schwarz Pharma Ltd Synthesis of phenolic esters of hydroxymethyl phenols
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
KR101488740B1 (ko) 2006-06-12 2015-02-03 유씨비 파마 게엠베하 새로운 키랄 중간체, 그 키랄 중간체의 제조방법 및 톨테로딘, 페소테로딘 또는 그 활성대사물질의 제조에서 그키랄 중간체의 사용
BRPI0713314A2 (pt) * 2006-06-20 2012-03-06 Lek Pharmaceuticals D.D. Processo para a preparação de 3-(2-hidróxi-5-fenil substituído)-n-alquil-3-fenilpropilaminas
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
MX2011011937A (es) * 2009-05-11 2012-01-27 Ratiopharm Gmbh Desfesoterodina en la forma de una sal del acido tartarico.
IT1394217B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
IT1394219B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
ES2456866T3 (es) 2009-07-27 2014-04-23 Crystal Pharma, S.A.U. Procedimiento para la obtención de 3,3-difenilpropilaminas
IT1396373B1 (it) 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
EP2364966A1 (en) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine
WO2011141932A2 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
CA2873721C (en) 2012-05-04 2021-06-22 Crystal Pharma, S.A.U. Process for the preparation of optically active 3,3-diphenylpropylamines
HRP20160363T1 (hr) 2012-06-14 2016-06-17 Ratiopharm Gmbh Soli desfesoterodina
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2016148444A1 (ko) * 2015-03-17 2016-09-22 제이더블유중외제약 주식회사 신규 데스페소테로딘 유도체, 이의 약제학적으로 허용되는 염 및 이를 포함하는 약제학적 조성물
WO2017137955A1 (en) 2016-02-14 2017-08-17 Celestis Pharmaceuticals Pvt. Ltd. Novel (r) and rac 3-(2-(allyloxy)-5-methylphenyl)-n,n-diisopropyl-3- phenylpropan-1-amine and its use for synthesis of (r) and rac-2-(3- (diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol
CN110372571B (zh) * 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111894A (no) * 1962-11-15
GB1169944A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof
GB1169945A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
US4139537A (en) 1976-06-29 1979-02-13 Cooper Laboratories, Inc. 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma

Also Published As

Publication number Publication date
HK1006349A1 (en) 1999-02-19
AU672458B2 (en) 1996-10-03
CA2148827C (en) 2005-01-04
DE69317898T2 (de) 1998-10-15
US5686464A (en) 1997-11-11
US5559269A (en) 1996-09-24
HUT72742A (en) 1996-05-28
FI952179A0 (fi) 1995-05-05
JP3343256B2 (ja) 2002-11-11
WO1994011337A1 (en) 1994-05-26
HU9501329D0 (en) 1995-06-28
FI120256B (fi) 2009-08-31
AU5438094A (en) 1994-06-08
DE69317898D1 (de) 1998-05-14
USRE40851E1 (en) 2009-07-14
ES2117155T3 (es) 1998-08-01
EP0667852B1 (en) 1998-04-08
FI952179A7 (fi) 1995-05-05
EP0667852A1 (en) 1995-08-23
HU224916B1 (en) 2006-04-28
NO951775D0 (no) 1995-05-05
CA2148827A1 (en) 1994-05-26
ATE164828T1 (de) 1998-04-15
DK0667852T3 (da) 1999-01-11
USRE39667E1 (en) 2007-05-29
JPH08503208A (ja) 1996-04-09
SE9203318D0 (sv) 1992-11-06
NO305477B1 (no) 1999-06-07

Similar Documents

Publication Publication Date Title
NO951775D0 (no) Nye 3,3-difenylpropylaminer, deres anvendelse og fremstilling
ES2029384T4 (es) Procedimiento para preparar nuevas 3,3-difenilpropilaminas.
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
ZA935276B (en) 3-(hydroxybenzylidenyl)-indolin-2-ones processes for their preparation and pharmaceutical compositions containing them
AU4616893A (en) New benzopyran compounds, process for their preparation and the pharmaceutical compositions which contain them
HU895648D0 (en) Process for the preparation of n,n-disubstituted diaryl-alkancarboxylic acid amide derivatives and pharmaceutical compositions containing such compounds
GR3021765T3 (en) Aminoalkylchomones, process for their preparation and pharmaceutical compositions containing them.
DK143483A (da) Fremgangsmaade til fremstilling af enantiomerer af substituerede fenylazacykloalkaner
ZA941056B (en) (Cyclohexyl)alkene compounds processes for preparing them and pharmaceutical compositions containing them
AU659738B2 (en) New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
AR009445A1 (es) Compuestos n-(piridinilamino)isoindolinas y compuestos relacionados, composiciones farmaceuticas, usos en la fabricacion de medicamentos para eltratamiento de la disfuncion de la memoria y la depresion, procedimiento de preparacion de dichos compuestos y compuestos intermediarios

Legal Events

Date Code Title Description
MK1K Patent expired